- Home
- MGRX vs POAI Comparison
MGRX vs POAI Comparison
Compare MGRX & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- POAI
- Stock Information
- Founded
- MGRX 2021
- POAI 2002
- Country
- MGRX United States
- POAI United States
- Employees
- MGRX N/A
- POAI N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- POAI Industrial Specialties
- Sector
- MGRX Technology
- POAI Health Care
- Exchange
- MGRX Nasdaq
- POAI Nasdaq
- Market Cap
- MGRX 8.1M
- POAI 8.9M
- IPO Year
- MGRX 2023
- POAI N/A
- Fundamental
- Price
- MGRX $1.50
- POAI $0.79
- Analyst Decision
- MGRX
- POAI Hold
- Analyst Count
- MGRX 0
- POAI 1
- Target Price
- MGRX N/A
- POAI N/A
- AVG Volume (30 Days)
- MGRX 160.2K
- POAI 159.3K
- Earning Date
- MGRX 08-13-2025
- POAI 08-12-2025
- Dividend Yield
- MGRX N/A
- POAI N/A
- EPS Growth
- MGRX N/A
- POAI N/A
- EPS
- MGRX N/A
- POAI N/A
- Revenue
- MGRX $511,084.00
- POAI $1,729,269.00
- Revenue This Year
- MGRX N/A
- POAI $486.27
- Revenue Next Year
- MGRX N/A
- POAI $65.50
- P/E Ratio
- MGRX N/A
- POAI N/A
- Revenue Growth
- MGRX N/A
- POAI 24.17
- 52 Week Low
- MGRX $1.32
- POAI $0.55
- 52 Week High
- MGRX $7.66
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- MGRX 45.69
- POAI 33.09
- Support Level
- MGRX $1.41
- POAI $0.73
- Resistance Level
- MGRX $2.04
- POAI $0.86
- Average True Range (ATR)
- MGRX 0.17
- POAI 0.05
- MACD
- MGRX -0.02
- POAI -0.00
- Stochastic Oscillator
- MGRX 33.43
- POAI 38.43
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.